Publication details

Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

Authors	MAUREL Marine HOWARD Jennifer KISSLING Esther POZO Francisco PEREZ-GIMENO Gloria BUDA Silke SEVE Noemie MCK-ENNA Adele MEIJER Adam RODRIGUES Ana Paula MARTINEZ-BAZ Ivan MLINARIC Ivan LATORRE-MARGALEF Neus TURI Gergo LAZAR Mihaela MAZAGATOS Clara ECHEVERRIA Aitziber ABELA Stephen BOURGEOIS Marc MACHADO Ausenda DUERRWALD Ralf PETROVIC Goranka OROSZI Beatrix JANCORIENE Ligita MARIN Alexandru HUSA Petr DUFFY Roisin DIJKSTRA Frederika GARCIA Virtudes Gallardo GOERLITZ Luise ENOUF Vincent BENNETT Charlene HOOIVELD Mariette GUIOMAR Raquel TROBAJO-SANMARTIN Camino VUCINA Vesna Visekruna HAGEY Tove Samuelsson AZEVEDO Ana Sofia Lameiras CASTILLA Jesus XUEREB Gerd DELAERE Benedicte GOMEZ Veronica TOLKSDORF Kristin BACCI Sabrina NICOLAY Nathalie KACZMAREK Marlena ANGELA MC Rose
Year of publication	2024
Type	Article in Periodical
Magazine / Source	EUROSURVEILLANCE
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.8.2400089
Doi	http://dx.doi.org/10.2807/1560-7917.ES.2024.29.8.2400089
Keywords	Influenza A vaccine effectiveness; European primary care; hospital multicentre studies
Description	Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU -PC) and hospital (EU -H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU -PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU -H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.